Targeting hypoxia-inducible factor-1α (HIF-1α) in combination with antiangiogenic therapy: a phase I trial of bortezomib plus bevacizumab
Falchook, Gerald S, Wheler, Jennifer J, Naing, Aung, Jackson, Edward F, Janku, Filip, Hong, David, Ng, Chaan S, Tannir, Nizar M, Lawhorn, Kristie N, Huang, Mei, Angelo, Laura S, Vishwamitra, Deeksha, Hess, Kenneth, Howard, Adrienne N, Parkhurst, Kristin L, Amin, Hesham M, Kurzrock, Razelle
Published in Oncotarget (15.11.2014)
Published in Oncotarget (15.11.2014)
Get full text
Journal Article
Phase II study of the antiangiogenesis agent thalidomide in recurrent or metastatic squamous cell carcinoma of the head and neck
Tseng, Jennifer E., Glisson, Bonnie S., Khuri, Fadlo R., Shin, Dong M., Myers, Jeffrey N., El‐Naggar, Adel K., Roach, Jennifer S., Ginsberg, Lawrence E., Thall, Peter F., Wang, Xuemei, Teddy, Stephanie, Lawhorn, Kristie N., Zentgraf, Rebecca E., Steinhaus, Ganene D., Pluda, James M., Abbruzzese, James L., Hong, Waun Ki, Herbst, Roy S.
Published in Cancer (01.11.2001)
Published in Cancer (01.11.2001)
Get full text
Journal Article
Conference Proceeding